CINECA IRIS Institutional Research Information System

VITALE, Candida
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.055
EU - Europa 912
AS - Asia 414
SA - Sud America 28
AF - Africa 21
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 2
Totale 3.446
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.014
IT - Italia 358
CN - Cina 154
DE - Germania 113
FR - Francia 94
VN - Vietnam 68
IN - India 54
CZ - Repubblica Ceca 49
GB - Regno Unito 46
JP - Giappone 40
RU - Federazione Russa 37
CA - Canada 33
IE - Irlanda 32
NL - Olanda 32
PL - Polonia 23
ES - Italia 20
HK - Hong Kong 18
SE - Svezia 17
KR - Corea 16
TR - Turchia 15
ZA - Sudafrica 15
AU - Australia 12
BR - Brasile 12
CH - Svizzera 11
CL - Cile 11
SG - Singapore 11
FI - Finlandia 10
MT - Malta 9
GR - Grecia 8
MK - Macedonia 8
PT - Portogallo 8
UA - Ucraina 8
IL - Israele 6
JO - Giordania 5
MY - Malesia 5
TT - Trinidad e Tobago 5
TW - Taiwan 5
AT - Austria 4
BE - Belgio 4
HU - Ungheria 4
RO - Romania 4
DK - Danimarca 3
ID - Indonesia 3
SA - Arabia Saudita 3
BG - Bulgaria 2
CO - Colombia 2
IQ - Iraq 2
IR - Iran 2
LT - Lituania 2
MA - Marocco 2
MX - Messico 2
NZ - Nuova Zelanda 2
PK - Pakistan 2
RS - Serbia 2
SI - Slovenia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AR - Argentina 1
BJ - Benin 1
BY - Bielorussia 1
EC - Ecuador 1
EG - Egitto 1
ET - Etiopia 1
EU - Europa 1
HN - Honduras 1
LB - Libano 1
MO - Macao, regione amministrativa speciale della Cina 1
NO - Norvegia 1
PE - Perù 1
PH - Filippine 1
QA - Qatar 1
TH - Thailandia 1
TN - Tunisia 1
Totale 3.446
Salva come PNG Salva come JPEG
Città #
Fairfield 208
Ashburn 174
Santa Cruz 172
Houston 124
Seattle 120
Buffalo 104
Woodbridge 95
Torino 82
Ann Arbor 81
Wilmington 77
Cambridge 60
Dong Ket 53
Chicago 33
Shanghai 32
Beijing 31
Dublin 29
San Diego 26
Los Angeles 23
Turin 23
Milan 20
Frankfurt Am Main 17
Las Vegas 17
Warsaw 16
Duncan 15
Ottawa 15
Stuttgart 15
Muizenberg 14
Pisa 14
Boardman 13
Clearwater 13
Dallas 13
New York 13
Nanjing 12
Chennai 11
Mountain View 11
Rome 9
University Park 9
Wuhan 9
Henderson 8
Menlo Park 8
Tokyo 8
Bengaluru 7
Helsinki 7
Lake Forest 7
Seoul 7
Amsterdam 6
Boston 6
Chongqing 6
London 6
Luton 6
Miami 6
Provo 6
San Francisco 6
Toronto 6
Bologna 5
Denver 5
Detroit 5
Guangzhou 5
Hartford 5
Hyderabad 5
Madrid 5
Mumbai 5
Münster 5
Phoenix 5
Port of Spain 5
Prilep 5
Providence 5
Redmond 5
Taipei 5
Xian 5
Amman 4
Athens 4
Budapest 4
Chengdu 4
Hangzhou 4
Hedemora 4
Lucknow 4
Monteriggioni 4
Rochester 4
Singapore 4
Tong 4
Augusta 3
Castiglione 3
Chandler 3
Cologne 3
Columbus 3
Grove City 3
Jakarta 3
Jerusalem 3
Livorno 3
Melbourne 3
Moscow 3
Paris 3
Pasadena 3
Recife 3
Riva 3
Roccadaspide 3
Saint Petersburg 3
Salt Lake City 3
San Jose 3
Totale 2.090
Salva come PNG Salva come JPEG
Nome #
Adoptive immunotherapy with CAR modified T cells in cancer: current landscape and future perspectives, file e27ce42e-9d5b-2581-e053-d805fe0acbaa 494
Richter Syndrome in Chronic Lymphocytic Leukemia, file e27ce42e-2edd-2581-e053-d805fe0acbaa 284
Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma, file e27ce427-79db-2581-e053-d805fe0acbaa 231
Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells, file e27ce427-83a5-2581-e053-d805fe0acbaa 206
CAR T-Cell Therapy for B-Cell non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Clinical Trials and Real-World Experiences, file e27ce430-de00-2581-e053-d805fe0acbaa 169
The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice, file e27ce430-d7e2-2581-e053-d805fe0acbaa 156
IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells, file e27ce426-c0e0-2581-e053-d805fe0acbaa 152
Magic pills: new oral drugs to treat chronic lymphocytic leukemia, file e27ce42b-6be3-2581-e053-d805fe0acbaa 105
Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib, file e27ce42e-2ed7-2581-e053-d805fe0acbaa 98
Chronic lymphocytic leukemia therapy: new targeted therapies on the way, file e27ce42e-30e6-2581-e053-d805fe0acbaa 98
Ofatumumab and lenalidomide for patients with relapsed or refractory chronic lymphocytic leukemia: Correlation between responses and immune characteristics, file e27ce42e-2edf-2581-e053-d805fe0acbaa 97
Lenalidomide can be safely combined with chlorambucil and rituximab in older patients with chronic lymphocytic leukemia, file e27ce42e-2ed5-2581-e053-d805fe0acbaa 96
Autoimmune complications in chronic lymphocytic leukemia in the era of targeted drugs, file e27ce42f-ab31-2581-e053-d805fe0acbaa 95
t(9;22) as secondary alteration in core-binding factor de novo acute myeloid leukemia, file e27ce42e-2edb-2581-e053-d805fe0acbaa 93
HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia, file e27ce42e-ef9d-2581-e053-d805fe0acbaa 92
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab, file e27ce430-d7e7-2581-e053-d805fe0acbaa 92
Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia, file e27ce42a-8c1f-2581-e053-d805fe0acbaa 85
Elevated lactate dehydrogenase has prognostic relevance in treatment-naïve patients affected by chronic lymphocytic leukemia with trisomy 12, file e27ce42f-52b0-2581-e053-d805fe0acbaa 78
Real life use of bendamustine in elderly patients with lymphoid neoplasia, file e27ce432-2046-2581-e053-d805fe0acbaa 74
Immunotherapeutic strategies in chronic lymphocytic leukemia: advances and challenges, file e27ce434-b0d8-2581-e053-d805fe0acbaa 73
Old and New Drugs for Chronic Lymphocytic Leukemia: Lights and Shadows of Real-World Evidence, file e27ce435-5dbe-2581-e053-d805fe0acbaa 67
HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia, file e27ce430-5244-2581-e053-d805fe0acbaa 65
Targeted Treatment of Chronic Lymphocytic Leukemia: Clinical Utility of Acalabrutinib, file e27ce434-75ae-2581-e053-d805fe0acbaa 64
Targeting hif-1α regulatory pathways as a strategy to hamper tumor-microenvironment interactions in cll, file e27ce432-7ca5-2581-e053-d805fe0acbaa 57
Cd200 baseline serum levels predict prognosis of chronic lymphocytic leukemia, file e27ce432-33fb-2581-e053-d805fe0acbaa 50
Prognostic relevance of oxidative stress measurement in chronic lymphocytic leukaemia, file e27ce42b-eff7-2581-e053-d805fe0acbaa 49
Prognostic significance of PET/CT in patients with chronic lymphocytic leukemia (CLL) treated with frontline chemoimmunotherapy, file e27ce430-d7ea-2581-e053-d805fe0acbaa 48
Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study, file e27ce434-84a6-2581-e053-d805fe0acbaa 48
Impact of immune parameters and immune dysfunctions on the prognosis of patients with chronic lymphocytic leukemia, file e27ce432-2f60-2581-e053-d805fe0acbaa 41
Regulation of HIF-1α in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role as a Therapeutic Target, file e27ce42e-24b0-2581-e053-d805fe0acbaa 39
Centralized Biobanking Supports Hematology Clinical Trials: the new challenge of the University of Torino, file e27ce42e-70fd-2581-e053-d805fe0acbaa 38
Prognostic impact and risk factors of infections in patients with chronic lymphocytic leukemia treated with ibrutinib, file e27ce432-6f0a-2581-e053-d805fe0acbaa 36
Case Report: Sequential Development of Three Mature Lymphoid Neoplasms in a Single Patient: Clonal Relationship and Molecular Insights, file 79f96122-4c5d-4b19-a66a-786e84540e13 28
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model, file e27ce434-e83c-2581-e053-d805fe0acbaa 27
Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma, file e27ce427-b3d4-2581-e053-d805fe0acbaa 17
Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study, file 0817f5cc-ee83-49d2-98fc-280183402ab5 11
Acute promyelocytic leukemia presented as a relapse of acute myeloid leukemia, file e27ce42e-24ac-2581-e053-d805fe0acbaa 11
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study, file f5cfad19-82df-42a0-bc27-958e510cc815 11
IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells, file e27ce426-c0e1-2581-e053-d805fe0acbaa 6
Bleeding diathesis associated with acquired von Willebrand Syndrome in three patients with chronic lymphocytic leukemia, file e27ce42e-2ed9-2581-e053-d805fe0acbaa 6
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL, file 563bac55-0461-4c9c-8eae-a9e1c40bbc84 5
High rate of durable responses with undetectable minimal residual disease with frontline venetoclax and rituximab in young and fit patients with chronic lymphocytic leukemia and an adverse biologic profile: results of the gimema phase II LLC1518 - 'Veritas' study, file 64042bde-855f-4f15-893a-87806cc7eecc 5
Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia, file 07df7579-f01c-4a60-afc4-c5a8b1de867a 4
Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter Study, file 70f16a90-befe-4e60-815c-e7e5232e2876 2
IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells, file e27ce426-c0df-2581-e053-d805fe0acbaa 2
Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells., file e27ce426-ef1f-2581-e053-d805fe0acbaa 2
A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia, file e27ce427-080e-2581-e053-d805fe0acbaa 2
Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemia, file e27ce42e-30e4-2581-e053-d805fe0acbaa 2
Anti-tumor activity of selinexor in combination with antineoplastic agents in chronic lymphocytic leukemia, file 28786943-7cfe-4e63-83ba-0c5952e029bf 1
CAR-modified Cellular Therapies in Chronic Lymphocytic Leukemia: Is the Uphill Road Getting Less Steep?, file 312f13fb-4af7-48e6-a7fa-6240f59d17c3 1
What Does Atypical Chronic Lymphocytic Leukemia Really Mean? A Retrospective Morphological and Immunophenotypic Study, file ceb3bb75-0cc6-4408-b8d4-2b5a3c689bfd 1
Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia, file e27ce42a-be6b-2581-e053-d805fe0acbaa 1
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY, file f65f4953-cfab-451d-b00d-5b440aab43b0 1
Totale 3.616
Salva come PNG Salva come JPEG
Categoria #
all - tutte 5.954
article - articoli 0
book - libri 0
conference - conferenze 169
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.123
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019105 0 0 0 0 0 0 0 0 0 18 61 26
2019/2020401 16 9 9 35 30 17 44 56 74 40 34 37
2020/2021851 41 86 56 65 85 81 86 64 52 81 48 106
2021/2022956 82 33 44 75 79 57 76 68 61 83 216 82
2022/2023704 18 32 181 96 29 48 52 58 90 37 53 10
2023/2024304 30 15 32 28 43 26 52 51 20 7 0 0
Totale 3.616